Fungi · Scientific monograph
Antrodia cinnamomea
Niu Zhang Zhi
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Hepatic / Liver Mechanisms, Cellular & Immune Studies, Inflammatory Pathways
Research overview
Historical use
Endemic to Taiwan, where it grows exclusively on the inner cavity of Cinnamomum kanehirai (Taiwanese sassafras). Known locally as 'Zhang Zhi' or 'Niu Zhang Zhi'. Used in Taiwanese indigenous medicine and folk medicine for centuries as a treatment for liver disease, abdominal pain, diarrhoea, and as a hangover remedy. Historically one of the most expensive medicinal fungi in Taiwan.
Modern research context
Hepatoprotective and anti-tumour properties are the primary research focus. Clinical evidence supports hepatoprotective activity in patients with non-alcoholic steatohepatitis (NASH) [1] and in sub-health adults [2]. Polysaccharide intervention modulates clinical symptoms likely via gut microbiome regulation [3]. Anti-proliferative activity against prostate cancer via immune modulation has been documented [4]. Hepatoprotective mechanisms are further supported by preclinical data showing reduction of hepatotoxicity in rodent models [5]. Antroquinonol, a unique ubiquinone derivative, has entered Phase II clinical trials in Taiwan.
Adverse effects
Generally well tolerated. Mild GI symptoms. Rare hypersensitivity. Potential QT interval prolongation with high doses (preclinical).
Contraindications
Hepatotoxic drugs — monitor liver function. Anticoagulants — theoretical additive effect. Drugs affecting QT interval — use with caution (preclinical signal).
Clinical and phytochemical data
Used part
Fruiting body and mycelium
Primary active compounds
Antroquinonol (4-hydroxy-2,3-dimethoxy-6-methyl-cyclohex-2-enone derivative)
Triterpenoids (antcin A, B, C, K)
Polysaccharides
Maleic/succinic acid derivatives
Ergosterol peroxide
Mechanism of action
Antroquinonol inhibits Ras/Akt/mTOR signalling, inducing tumour cell autophagy and apoptosis; also inhibits HIF-1α, reducing hypoxia-driven VEGF expression (anti-angiogenic). Triterpenoids inhibit NF-κB pathway, reducing IL-6, TNF-α, and COX-2. Hepatoprotective via Nrf2/HO-1 upregulation and suppression of CYP2E1-mediated oxidative stress.
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Intestinal absorption of 14 ergostane and lanostane triterpenoids from Antrodia cinnamomea was characterised using a bidirectional Caco-2 cell monolayer model; most triterpenoids showed low-to-moderate intestinal permeability, consistent with their high lipophilicity [1]. No human oral bioavailability data are available. Antroquinonol bioavailability ~20% in rodents. Triterpenoid absorption limited; improved by lipid-based formulation. Human PK data emerging from Phase I/II trials.
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Antroquinonol and ubiquinone derivatives are highly lipophilic; distribute to tumour vasculature, liver, and adipose tissue. Significant hepatic first-pass metabolism expected. Half-life of antroquinonol estimated at ~4–6 hours in preclinical models. No formal human PK distribution data available.
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Hepatic CYP3A4-mediated metabolism of triterpenoids. Antroquinonol undergoes phase II conjugation.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Biliary/fecal for triterpenoids; renal for water-soluble metabolites.
Safety and interactions
Drug interactions
Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.
Toxicity
LD50 >5 g/kg for whole extract (rodents). Antroquinonol demonstrated an acceptable tolerability profile in Phase I clinical evaluation. QT prolongation was observed at suprapharmacological doses in preclinical studies — clinical significance at therapeutic doses is unclear; long-term safety data are limited to early-phase clinical experience.
Special precautions
Pregnancy
Insufficient clinical data. Potent bioactivity warrants avoidance during pregnancy.
Lactation
No data on breast milk excretion. Avoid during breastfeeding.
Hepatic impairment
Paradox: hepatoprotective in documented trials, but CYP metabolism may be impaired; monitor carefully and start at low doses.
Renal impairment
No specific data. Standard monitoring recommended.
Sources and references
- [1] - Chiou YL., "Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis.", J Am Coll Nutr, 2021, PMID: 32657670
- [2] - Ho CY., "Hepatoprotective effect of Antrodia Cinnamomea mycelia extract in subhealth Japanese adults: a double-blind, placebo-controlled clinical trial.", J Diet Suppl, 2023, PMID: 36476310
- [3] - Liu ZQ., "Dietary Antrodia cinnamomea Polysaccharide Intervention Modulates Clinical Symptoms by Regulating Gut Microbiota.", J Agric Food Chem, 2024, PMID: 39632724
- [4] - Tsai MY., "Antrodia cinnamomea Formula Suppresses Prostate Cancer Progression via Immune Modulation and Androgen Receptor Pathway Inhibition.", Int J Mol Sci, 2025, PMID: 40141325
- [5] - Shih YL., "Antrodia Cinnamomea Reduces Carbon Tetrachloride-induced Hepatotoxicity in Male Wistar Rats.", In Vivo, 2017, PMID: 28882954